Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy Davis

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 12, 2009
Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular deliveryLouise R Rodino-Klapac, Chrystal L Montgomery, William G Bremer, et al.
Future Oncology (London, England)|September 1, 2025
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapyPetros Grivas, Scott T Tagawa, Rohit K Jain, et al.
Journal of AHIMA|August 5, 2008
Mitigating medical identity theftChris Apgar, Gordon Apple, Larry Ayers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor TherapyDaniel P Petrylak, Scott T Tagawa, Rohit K Jain, et al.
JAMA Oncology|September 1, 2022
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical TrialNizar M Tannir, Neeraj Agarwal, Camillo Porta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerMatthew D Galsky, Amir Mortazavi, Matthew I Milowsky, et al.
European Urology Oncology|December 17, 2023
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial CarcinomaPavlos Msaouel, Randy F Sweis, Manojkumar Bupathi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2020
Systemic Therapy for Melanoma: ASCO GuidelineRahul Seth, Hans Messersmith, Varinder Kaur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2023
Systemic Therapy for Melanoma: ASCO Guideline UpdateRahul Seth, Sanjiv S Agarwala, Hans Messersmith, et al.
Clinical Genitourinary Cancer|February 5, 2026
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE DatabaseAlbert Jang, Tanya Jindal, Ali Raza Khaki, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 12, 2009
Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular deliveryLouise R Rodino-Klapac, Chrystal L Montgomery, William G Bremer, et al.
Future Oncology (London, England)|September 1, 2025
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapyPetros Grivas, Scott T Tagawa, Rohit K Jain, et al.
Journal of AHIMA|August 5, 2008
Mitigating medical identity theftChris Apgar, Gordon Apple, Larry Ayers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor TherapyDaniel P Petrylak, Scott T Tagawa, Rohit K Jain, et al.
JAMA Oncology|September 1, 2022
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical TrialNizar M Tannir, Neeraj Agarwal, Camillo Porta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerMatthew D Galsky, Amir Mortazavi, Matthew I Milowsky, et al.
European Urology Oncology|December 17, 2023
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial CarcinomaPavlos Msaouel, Randy F Sweis, Manojkumar Bupathi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2020
Systemic Therapy for Melanoma: ASCO GuidelineRahul Seth, Hans Messersmith, Varinder Kaur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2023
Systemic Therapy for Melanoma: ASCO Guideline UpdateRahul Seth, Sanjiv S Agarwala, Hans Messersmith, et al.
Clinical Genitourinary Cancer|February 5, 2026
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE DatabaseAlbert Jang, Tanya Jindal, Ali Raza Khaki, et al.
Pageof 6